Group 1 - *ST Tianmao's stock will be delisted on September 30, 2025 [1] - Duori Pharmaceutical is planning a change in control and will suspend trading from September 29 [2] - Zhonghuan Environmental is also planning a change in control and will suspend trading from September 29 [3] Group 2 - Yidao Information is planning to acquire Langguo Technology and become its controlling shareholder, suspending trading from September 29 [3] - Zhiguang Electric is planning to purchase minority stakes in its subsidiary Zhiguang Energy, suspending trading from September 29 [4] - Guanzhong Ecology's controlling shareholder intends to change to Deep Blue Finance Whale, with trading resuming on September 29; the company plans to acquire 51% of Hangzhou Actuary [5] Group 3 - Xindazheng intends to acquire 75.15% of Jiaxin Liheng to expand its business reach [6] - Boqian New Materials signed a strategic cooperation agreement, estimating sales of nickel powder products between 4.3 billion to 5 billion yuan [7] - Zhongxin Co. faces significant impact from the U.S. Department of Commerce's final ruling on anti-dumping investigations against thermoplastic molded fiber products from China and Vietnam [7] Group 4 - Xin Guang Optoelectronics' chairman and general manager, Kang Weimin, has been placed under detention measures [8] - Yalake Co. has commenced trial production for its 40,000 tons/year integrated lithium salt project [9] - United Precision's two actual controllers plan to collectively reduce their holdings by no more than 3% [10] Group 5 - Keli'er's actual controller and chairman, Nie Pengju, plans to reduce his holdings by no more than 2% [11] - Jinhaitong's Xunuo Investment plans to reduce its holdings by no more than 3% [12] - Jingsong Intelligent's Anyuan Investment plans to reduce its holdings by no more than 2.68% [13]

Core Viewpoint - Three A-share listed companies, Duori Pharmaceutical, Zhonghuan Environmental Protection, and Yatai Pharmaceutical, announced plans for changes in control, leading to stock suspension starting September 29, 2025 [1][2]. Company Summaries Duori Pharmaceutical - The controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd., and actual controller, Mr. Deng Yong, are planning a change in control, which may lead to a change in the controlling shareholder and actual controller [1]. - For the first half of the year, Duori Pharmaceutical reported revenue of approximately 107 million yuan, a year-on-year decrease of 29.13%, and a net profit attributable to shareholders of -42.5 million yuan, compared to -3.27 million yuan in the same period last year [4]. Zhonghuan Environmental Protection - The controlling shareholder, Mr. Zhang Bozhong, and his concerted party, Anhui Zhongchen Investment Holding Co., Ltd., are also planning a change in control [1]. - In the first half of the year, Zhonghuan Environmental Protection achieved total revenue of 474 million yuan, a year-on-year increase of 4.84%, and a net profit attributable to shareholders of 44.1 million yuan, up 9.69% [4]. Yatai Pharmaceutical - The controlling shareholder, Ningbo Fubang Holding Group Co., Ltd., and the management team are planning a change in control, with further discussions needed on the specific transaction plan and agreement terms [1]. - Yatai Pharmaceutical's stock price closed at 5.67 yuan per share on September 26, 2025, with a year-to-date market value increase of 85.9% [3]. - The company reported revenue of approximately 152 million yuan for the first half of the year, a year-on-year decrease of 31.48%, while the net profit attributable to shareholders was approximately 105 million yuan, a significant increase of 1820.97%. However, the non-recurring net profit was -48.86 million yuan [3][4].

Core Viewpoint - Duori Pharmaceutical is undergoing a potential change in control, which may lead to a shift in its major shareholder and actual controller, with stock suspension expected for no more than two trading days [1] Group 1: Company Overview - Duori Pharmaceutical primarily engages in the research, production, and sales of chemical drug formulations, intermediates, and active pharmaceutical ingredients [1] - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market in September 2021 [1] Group 2: Financial Performance - The company has experienced a continuous decline in net profit from 2021 to 2024, with figures of 68.51 million, 20.50 million, 18.85 million, and a loss of 62.67 million respectively, reflecting year-on-year decreases of 25.53%, 70.07%, 8.05%, and 432.44% [1][2] - Revenue has also decreased for three consecutive years, with 2022 to 2024 revenues of 401 million, 334 million, and 241 million, showing year-on-year declines of 24.28%, 16.64%, and 28.02% [2] - In the first half of 2025, revenue continued to decline to 107 million, a year-on-year decrease of 29.13%, with a net profit loss of 42.50 million compared to a loss of 3.28 million in the same period last year [2] Group 3: Profitability and Financial Ratios - The company's gross margin has sharply declined from 88.61% in 2021 to 42.42% in 2024, plummeting to 4.07% in the first half of 2025 [2] - The asset-liability ratio increased significantly from 23.37% at the end of 2023 to 50.91% at the end of 2024, further rising to 52.01% by mid-2025 [2]

Group 1: Control Change Announcements - Multiple A-share companies, including Duori Pharmaceutical, Asia-Pacific Pharmaceutical, and Zhonghuan Environmental Protection, announced plans for control changes on September 28 [1][3][4] - Duori Pharmaceutical's controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd., is planning a control change, leading to a potential change in the actual controller [1] - Asia-Pacific Pharmaceutical's controlling shareholder, Ningbo Fubang Holding Group Co., Ltd., is also planning a control change, with no formal agreement signed yet [3] - Zhonghuan Environmental Protection's controlling shareholder, Zhang Bozhong, is in the process of planning a control change, which may affect the actual controller [4] Group 2: Company Profiles and Operations - Duori Pharmaceutical specializes in the R&D, production, and sales of chemical drug formulations and intermediates, with leading market share in products like Acetate Sodium Ringer Injection [1] - Asia-Pacific Pharmaceutical focuses on pharmaceutical manufacturing, including the R&D and sales of chemical formulations, with a portfolio of 114 approved formulations [3] - Zhonghuan Environmental Protection is a national high-tech enterprise engaged in water environment governance and waste treatment, providing comprehensive solutions in various segments [5] - Guanzhong Ecology is undergoing a control change with a share transfer agreement to Deep Blue Whale, which will result in a new controlling shareholder [7]

多瑞医药（301075）(301075.SZ)公告，公司控股股东西藏嘉康时代科技发展有限公司(简称"西藏嘉 康")、实际控制人邓勇先生正在筹划公司控制权变更相关事宜，该事项可能导致公司控股股东、实际控 制人发生变更。公司股票自2025年9月29日(星期一)上午开市起停牌，预计停牌时间不超过2个交易日。 ...

智通财经APP讯，多瑞医药(301075.SZ)公告，公司控股股东西藏嘉康时代科技发展有限公司(简称"西藏 嘉康")、实际控制人邓勇先生正在筹划公司控制权变更相关事宜，该事项可能导致公司控股股东、实际 控制人发生变更。公司股票自2025年9月29日(星期一)上午开市起停牌，预计停牌时间不超过2个交易 日。 ...

多瑞医药表示，经公司向深交所申请，公司股票自9月29日上午开市起停牌，预计停牌时间不超过2个交 易日。 北京商报讯（记者 丁宁）9月28日晚间，多瑞医药（301075）发布公告称，公司控股股东西藏嘉康时代 科技发展有限公司、实际控制人邓勇正在筹划公司控制权变更相关事宜，该事项可能导致公司控股股 东、实际控制人发生变更。 ...

人民财讯9月28日电，多瑞医药（301075）9月28日公告，控股股东西藏嘉康时代科技发展有限公司、实 控人邓勇正在筹划公司控制权变更相关事宜，该事项可能导致公司控股股东、实控人发生变更。经申 请，公司股票9月29日开市起停牌，预计停牌不超2个交易日。 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2025-075 西藏多瑞医药股份有限公司 控股股东西藏嘉康时代科技发展有限公司、实际控制人邓勇先生 保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 特别提示 1、西藏多瑞医药股份有限公司（以下简称"多瑞医药"或"公 司"）控股股东西藏嘉康时代科技发展有限公司（以下简称"西藏嘉 康"）、实际控制人邓勇先生正在筹划公司控制权变更相关事宜，该事 项可能导致公司控股股东、实际控制人发生变更。经公司向深圳证券 交易所申请，公司股票（股票简称：多瑞医药，股票代码：301075） 自 2025 年 9 月 29 日（星期一）上午开市起停牌，预计停牌时间不超 过 2 个交易日。 2、本次交易事项能否最终实施完成及实施结果尚存在不确定性， 敬请广大投资者关注后续公告并注意投资风险。 公司于 2025 年 9 月 26 日收到公司控股股东西藏嘉康时代科技发 展有限公司、实际控制人邓勇先生的通知，其正在筹划公司控制权变 更相关事宜，该事项可能导致公司控股股东、实际控制人发生变更。 目前各方尚未签署正式协议，正就具体交易方案、协议等相关事项进 行论证 ...

Group 1 - The core point of the article is that Duori Pharmaceutical is undergoing a potential change in control, which may affect its major shareholder and actual controller [1] - Duori Pharmaceutical's stock will be suspended from trading starting September 29, 2025, for a period not exceeding two trading days to ensure fair information disclosure and avoid abnormal stock price fluctuations [1] - As of the report, Duori Pharmaceutical has a market capitalization of 3.2 billion yuan [1] Group 2 - For the fiscal year 2024, Duori Pharmaceutical's revenue composition is 57.85% from the pharmaceutical manufacturing industry and 42.15% from other sources [1]